Article By:
Zacks Investment Research
Saturday, February 6, 2021 4:47 PM EST
Any positive news highlighting the progress of vaccine or antibody manufacturers is expected to create great returns for investors. Let’s take a look at some biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Alert: Alzheimer’s Drug Fails In Clinical Trial - Stocks Sink
What are the chances of $BIIB and $TSRO being bought out? They have long been targets, or at least rumored to be, for consolidation.